Phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) plus carboplatin and etoposide chemotherapy (chemo) or chemo alone for metastatic neuroendocrine prostate cancer (NEPC).

Authors: Gunhild Von Amsberg, Urban Emmenegger, Debbie GJ Robbrecht, Cagatay Arslan, Niven Mehra, Enrique Gonzalez-Billalabeitia, Mariusz Kwiatkowski, Margitta Retz, Fatih Köse, Mark David Linch, Brigitte Laguerre, Alessandra Mosca, Juan Carlos Vázquez Limón, Daniel A. Vaena, Christopher Eing Wee, Manuel Magallanes, Haixia Hu, Charles Schloss, Christian Heinrich Poehlein, Evan Y. Yu

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.5059

Source: Full article

---

Abstract

5059